SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to recent bullish momentum and community excitement around upcoming airdrops and staking. The community believes $BROKE has strong long-term potential, citing the active developer, engaged community, and plans for future utilities as reasons for its upward trajectory. Many community members are actively participating in a buy contest, and anticipating a new ATH.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential, highlighting its speed and efficiency compared to other blockchains like Ethereum. Discussions also involve meme coins built on Solana, with some users anticipating a strong rally. Additionally, the recent Alpenglow upgrade, aimed at boosting transaction speeds, has generated buzz.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending due to a significant stock drop following a weaker-than-expected outlook, driven by tariff concerns and slowing US sales. Community discussions revolve around whether this dip presents a buying opportunity, with some citing international growth potential and others highlighting increased competition and changing consumer preferences. The overall sentiment is bearish, with analysts downgrading the stock and investors questioning the company's growth strategy.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending amid high trading volume and social media buzz, with community members actively discussing potential short squeezes and a climb towards a target price of $10. Speculation around upcoming news, such as a new CEO announcement, and broader market factors, like potential interest rate cuts, appear to be fueling optimism. Despite some bearish sentiment and a recent critical report from Citron Research, many investors express confidence in OPEN's long-term potential.

Krypto Cock is a meme-powered crypto project with real onchain utility. Born from the lessons of past market cycles, $COCK blends humor, culture, and technology to create a unique community-driven ecosystem.  The project is focused on: • Building lightweight mini-apps for Farcaster and other onchain platforms • Developing an engaged, growing community • Delivering consistent, high-quality content • Offering practical onchain tools and experiences • Led by a team with years of crypto and product experience  $COCK aims to make the crypto experience more fun, accessible, and connected, without sacrificing purpose or quality.

CockCardano

$COCK.X is trending as the community rallies around the upcoming launch of Cocky Wings LLC, a real-world food business associated with the Cardano-based meme coin. Community members highlight the potential for passive income through staking and are excited about the partnership with $SNEK.X and the presence at the South Carolina Gamecocks home game.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

$SNAP is trending as traders discuss potential catalysts including AI integration, a possible buyout, and speculation around increased interest from Reddit's WallStreetBets community. Community members are actively debating price targets, potential acquirers, and the impact of AI on the platform's future, while also noting the stock's high short interest and recent trading volume.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending amid discussions about its new corporate name and ticker symbol after Overstock acquired the rights, sparking confusion among investors. The community is buzzing about the potential of Tzero, a blockchain platform associated with the company, and its possible impact on preventing naked shorting, drawing comparisons to the $GME saga. Some traders are expressing skepticism while others speculate on Ryan Cohen's next move and the potential for new stores.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a recent analyst downgrade impacting investor sentiment, while some community members view the dip as a buying opportunity. Community talking points include the sustainability of AMD's growth, competition with NVIDIA and Broadcom, and potential price targets. Despite the selloff, some express confidence in AMD's long-term prospects, particularly in the AI and data center markets.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending upward following a strong earnings report and guidance, with analysts citing significant AI-fueled revenue growth, leading to numerous target price increases. Community members are focused on a reported partnership with OpenAI for AI chips, which has further boosted optimism. Traders are discussing potential short squeezes and whether Broadcom is positioned to challenge competitors in the AI space.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending as the FDA considers the ineffectiveness of phenylephrine, an ingredient in popular decongestants like Sudafed PE, potentially impacting sales. Despite this, some analysts remain bullish, citing attractive entry points and a recent addition to the S&P 500, with the community actively monitoring price movements for potential buying opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

Equity

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.


The U.S. Food and Drug Administration may reportedly fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other countries.FDA Commissioner Marty Makary floated the idea in an <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-11/fda-offers-to-trade-faster-drug-reviews-for-lower-us-prices">interview</a> on Bloomberg Television. Makary said that price adjustments may give companies another way to obtain “national priority vouchers” under the program announced last month.As part of the <a href="https://stocktwits.com/news-articles/markets/equity/fda-aims-to-reduce-drug-application-review-time-with-new-voucher-program/chlp5PzRRce">program</a>, the FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten the review time from approximately 10-12 months to one or two months after the company submits its final drug application.According to the initial plan, the agency will distribute a limited number of vouchers to companies aligned with the U.S.’ national priorities in the first year, the FDA stated, without naming any specific companies.“We can issue a national priority review voucher for companies that are promising to equalize the price” between the US and what other foreign countries pay, Makary said.“We want to incentivize good behavior in the marketplace, and these priority vouchers are worth a lot of money,” he added while noting that the program could be used as a means to even out drug prices with those currently charged in places like Europe.Trump <a href="https://stocktwits.com/news-articles/markets/equity/merck-pfizer-eli-lilly-stocks-rebound-as-trump-targets-drug-costs-with-new-executive-order/chiN18ERbmL">signed</a> an executive order in May intended to match U.S. drug prices with those of other developed countries in order to lower domestic healthcare costs.“The United States has less than five percent of the world’s population and yet funds around three-quarters of global pharmaceutical profits,” Trump said.“Americans will no longer be forced to pay almost three times more for the exact same medicines, often made in the exact same factories. As the largest purchaser of pharmaceuticals, Americans should get the best deal.”Makary, on Friday, did not detail how drugmakers have to adjust prices to qualify for a voucher, Bloomberg said. The report added that it is also unclear how much of an impact the vouchers would have and that the FDA has typically avoided entering drug pricing in the U.S.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/mink-therapeutics-patient-received-full-remission-in-testicular-cancer-with-investigational-cell-therapy/ch8cWyDR5Zt">MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report

FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.

The U.S. Food and Drug Administration (FDA) on Tuesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/news-events/press-announcements/fda-issue-new-commissioners-national-priority-vouchers-companies-supporting-us-national-interests">announced </a>it is launching a voucher program to accelerate reviews of drug applications.The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten the review time from approximately 10-12 months to 1-2 months after the company submits its final drug application. &nbsp;The expedited process will convene experts from FDA offices for a team-based review, rather than using the standard review system, where a drug application is sent to numerous FDA offices.FDA Commissioner Marty Makary said that the program will allow companies to submit the “lion’s share” of the application before a clinical trial is complete.“The ultimate goal is to bring more cures and meaningful treatments to the American public,” he added.According to the current plan, the agency will distribute a limited number of vouchers to companies aligned with the U.S.’ national priorities in the first year, the FDA stated, without naming any specific companies.The companies should be either addressing a health crisis in the U.S., delivering more innovative cures, addressing unmet public health needs, or increasing domestic drug manufacturing as a national security issue.To qualify for the expedited review program, companies must submit the chemistry, manufacturing, and controls (CMC) portion of the application at least 60 days before submitting the final application. Companies must also be available for ongoing communication with the agency.Vouchers can be directed by the FDA towards a specific investigational new drug of a company or be granted to a company as an undesignated voucher, the FDA said.The agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/news-events/press-announcements/faqs-commissioners-national-priority-voucher-program">may</a> increase the number of vouchers it gives to companies after the first year, it added.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-dollar-sentiment-hits-two-decade-low-says-bank-of-america/chlpRTwRRc5">US Dollar Sentiment Hits Two-Decade Low, Says Bank Of America – Here’s What Investors Are Buying Instead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. Food and Drug Administration (FDA) Commissioner Martin Makary arrives for a Senate Appropriations Committee hearing on Capitol Hill on May 22, 2025 in Washington, DC. (Photo by Anna Moneymaker/Getty Images)

FDA Aims To Reduce Drug Application Review Time With New Voucher Program

The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final drug application.  

ETFs on the Move Post U.S.-China Trade Deal

BlackRock Institutional Trust Company N.A. - iShares U.S. Pharmaceuticals ETF

$APP

$MSTR

$HOOD

other (drop a comment)

The S&amp;P 500 rebalance announcement is today — which stock do you think has the best shot at getting added?

IHE
iShares U.S. Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IHE News

IHE iShares U.S. Pharmaceuticals ETF